Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294511" target="_blank" >RIV/00216208:11130/15:10294511 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10294511

Výsledek na webu

<a href="http://dx.doi.org/10.1111/bjh.13267" target="_blank" >http://dx.doi.org/10.1111/bjh.13267</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjh.13267" target="_blank" >10.1111/bjh.13267</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases

Popis výsledku v původním jazyce

Umbilical cord blood (UCB) from an human leucocyte antigen (HLA)-identical sibling can be used for transplantation of patients with malignant and non-malignant diseases. However, the low cellular content of most UCB units represents a limitation to thisapproach. An option to increase cell dose is to harvest bone marrow (BM) cells from the same donor and infuse them along with the UCB. We studied 156 children who received such a combined graft between 1992 and 2011. Median age was 7years and 78% of patients (n=122) were transplanted for non-malignant diseases, mainly haemoglobinopathies. Acute leukaemia (n=26) was the most frequent malignant diagnosis. Most patients (91%) received myeloablative conditioning. Median donor age was 17years, median infusednucleated cell dose was 244x10(7)/kg and median follow-up was 41months. Sixty-days neutrophil recovery occurred in 96% of patients at a median of 17d. The probabilities of grade-II-IV acute and chronic graft-versus-host disease (GVHD) we

Název v anglickém jazyce

Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases

Popis výsledku anglicky

Umbilical cord blood (UCB) from an human leucocyte antigen (HLA)-identical sibling can be used for transplantation of patients with malignant and non-malignant diseases. However, the low cellular content of most UCB units represents a limitation to thisapproach. An option to increase cell dose is to harvest bone marrow (BM) cells from the same donor and infuse them along with the UCB. We studied 156 children who received such a combined graft between 1992 and 2011. Median age was 7years and 78% of patients (n=122) were transplanted for non-malignant diseases, mainly haemoglobinopathies. Acute leukaemia (n=26) was the most frequent malignant diagnosis. Most patients (91%) received myeloablative conditioning. Median donor age was 17years, median infusednucleated cell dose was 244x10(7)/kg and median follow-up was 41months. Sixty-days neutrophil recovery occurred in 96% of patients at a median of 17d. The probabilities of grade-II-IV acute and chronic graft-versus-host disease (GVHD) we

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Haematology

ISSN

0007-1048

e-ISSN

—

Svazek periodika

169

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

103-110

Kód UT WoS článku

000351446400013

EID výsledku v databázi Scopus

2-s2.0-84925218324